Double melanoma win for GSK: FDA OK's Mekinist, Tafinlar
This article was originally published in Scrip
What GlaxoSmithKline thought was going to be delayed until September came early for the London pharma, with the FDA on 29 May not only approving Mekinist (trametinib) ahead of schedule but also granting a nod to Tafinlar (dabrafenib) – both drugs winning the agency's OK as treatments for metastatic or unresectable melanoma.
You may also be interested in...
The FDA approved Tafinlar/Mekinist for BRAF V600E-mutated solid tumors, based in part on a Phase II basket trial studying more than two dozen drugs across dozens of cancers based on genetic testing.
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.